Uncategorized

UT MD Anderson - Cancer Center's Gastrointestinal Medical Oncology Department held its inaugural Colorectal ctDNA Symposium on March 27, 2026.  A multidisciplinary group of clinicians and researchers from multiple institutions presented data and discussed how minimal residual disease detection can transform decision‑making, personalize therapy, and close the gap between discovery, community practice, and clinical trials. Over the next few months, video recordings from select symposium sessions will be posted as they can be released to the public. This initial video features Dr. Van Morris from UT MD Anderson - Cancer Center, who introduces and moderates the symposium. MD Anderson [...]

Survival for patients with metastatic colorectal cancer has improved steadily since 2012, according to retrospective study results. Researchers attributed this trend to several factors, including use of immunotherapy, surgical resection of liver metastases and use of third-line chemotherapy. The analysis included 1,420 patients with de novo metastatic colorectal cancer who received their primary treatment at The University of MD Anderson Cancer Center from 2004 through 2019. Despite survival improvements, results showed the majority of patients died within 5 years of diagnosis. This highlights the need for more study and the development of more effective therapeutic strategies, particularly targeted treatments, researchers concluded. Healio [...]